Combined modality therapy increasing local control of pancreatic cancer

Howard W. Bruckner, Shalom Kalnicki, Jack Dalton, Gary K. Schwartz, Margaret R. Chesser, John Mandeli, Cynthia Janus

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Twenty patients with inoperable locally advanced Stage II and III pancreatic cancer were treated with combined modality therapy. Radiotherapy consisted of split courses of 2000 cGy each and, as needed, an additional 1400 cGy, separated by 2-week intervals. Simultaneous multidrug regimen chemotherapy consisted of 5-fluorouracil, continuous infusion, 1 g/m2 days 1-5; streptozotocin, 300-500 mg/ m2 days 1, 2, 3; and cisplatin, 100 mg/m2 day 3 of every 4-week radiotherapy course (RT-FSP). Primary tumors decreased more than 50% in volume in II of 20 patients. Computed tomography scans demonstrated apparent complete disappearance of the primary tumor in 7 patients. Only 3 patients had tumor re growth within the radiotherapy field, all after the end of radiotherapy. Local control improved as measured by increased frequency of tumor shrinkage and decreased frequency of primary tumor growth, recognizing the limitations of a pilot study and comparisons to best historical results achieved with standard short 5-fluorouracil schedules and radiotherapy. Successful local control largely eliminates the most common cause of refractory pain and may decrease the need for some forms of early palliative surgical intervention. Tumor shrinkage sometimes downstages tumors, creating frequent investigational opportunities for either elective extirpative surgery or intraoperative radiotherapy. This pilot experience also supports testing of expanded eligibility staging criteria for combined modality treatment and testing of new drugs as part of 5-fluorouracil-radiotherapy-based regimens.

Original languageEnglish (US)
Pages (from-to)241-246
Number of pages6
JournalCancer Investigation
Volume11
Issue number3
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Combined Modality Therapy
Pancreatic Neoplasms
Radiotherapy
Neoplasms
Fluorouracil
Intractable Pain
Streptozocin
Growth
Cisplatin
Appointments and Schedules
Tomography
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bruckner, H. W., Kalnicki, S., Dalton, J., Schwartz, G. K., Chesser, M. R., Mandeli, J., & Janus, C. (1993). Combined modality therapy increasing local control of pancreatic cancer. Cancer Investigation, 11(3), 241-246. https://doi.org/10.3109/07357909309024847

Combined modality therapy increasing local control of pancreatic cancer. / Bruckner, Howard W.; Kalnicki, Shalom; Dalton, Jack; Schwartz, Gary K.; Chesser, Margaret R.; Mandeli, John; Janus, Cynthia.

In: Cancer Investigation, Vol. 11, No. 3, 1993, p. 241-246.

Research output: Contribution to journalArticle

Bruckner, HW, Kalnicki, S, Dalton, J, Schwartz, GK, Chesser, MR, Mandeli, J & Janus, C 1993, 'Combined modality therapy increasing local control of pancreatic cancer', Cancer Investigation, vol. 11, no. 3, pp. 241-246. https://doi.org/10.3109/07357909309024847
Bruckner, Howard W. ; Kalnicki, Shalom ; Dalton, Jack ; Schwartz, Gary K. ; Chesser, Margaret R. ; Mandeli, John ; Janus, Cynthia. / Combined modality therapy increasing local control of pancreatic cancer. In: Cancer Investigation. 1993 ; Vol. 11, No. 3. pp. 241-246.
@article{ccd0666839c04ac380f4f138fe5db106,
title = "Combined modality therapy increasing local control of pancreatic cancer",
abstract = "Twenty patients with inoperable locally advanced Stage II and III pancreatic cancer were treated with combined modality therapy. Radiotherapy consisted of split courses of 2000 cGy each and, as needed, an additional 1400 cGy, separated by 2-week intervals. Simultaneous multidrug regimen chemotherapy consisted of 5-fluorouracil, continuous infusion, 1 g/m2 days 1-5; streptozotocin, 300-500 mg/ m2 days 1, 2, 3; and cisplatin, 100 mg/m2 day 3 of every 4-week radiotherapy course (RT-FSP). Primary tumors decreased more than 50{\%} in volume in II of 20 patients. Computed tomography scans demonstrated apparent complete disappearance of the primary tumor in 7 patients. Only 3 patients had tumor re growth within the radiotherapy field, all after the end of radiotherapy. Local control improved as measured by increased frequency of tumor shrinkage and decreased frequency of primary tumor growth, recognizing the limitations of a pilot study and comparisons to best historical results achieved with standard short 5-fluorouracil schedules and radiotherapy. Successful local control largely eliminates the most common cause of refractory pain and may decrease the need for some forms of early palliative surgical intervention. Tumor shrinkage sometimes downstages tumors, creating frequent investigational opportunities for either elective extirpative surgery or intraoperative radiotherapy. This pilot experience also supports testing of expanded eligibility staging criteria for combined modality treatment and testing of new drugs as part of 5-fluorouracil-radiotherapy-based regimens.",
author = "Bruckner, {Howard W.} and Shalom Kalnicki and Jack Dalton and Schwartz, {Gary K.} and Chesser, {Margaret R.} and John Mandeli and Cynthia Janus",
year = "1993",
doi = "10.3109/07357909309024847",
language = "English (US)",
volume = "11",
pages = "241--246",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Combined modality therapy increasing local control of pancreatic cancer

AU - Bruckner, Howard W.

AU - Kalnicki, Shalom

AU - Dalton, Jack

AU - Schwartz, Gary K.

AU - Chesser, Margaret R.

AU - Mandeli, John

AU - Janus, Cynthia

PY - 1993

Y1 - 1993

N2 - Twenty patients with inoperable locally advanced Stage II and III pancreatic cancer were treated with combined modality therapy. Radiotherapy consisted of split courses of 2000 cGy each and, as needed, an additional 1400 cGy, separated by 2-week intervals. Simultaneous multidrug regimen chemotherapy consisted of 5-fluorouracil, continuous infusion, 1 g/m2 days 1-5; streptozotocin, 300-500 mg/ m2 days 1, 2, 3; and cisplatin, 100 mg/m2 day 3 of every 4-week radiotherapy course (RT-FSP). Primary tumors decreased more than 50% in volume in II of 20 patients. Computed tomography scans demonstrated apparent complete disappearance of the primary tumor in 7 patients. Only 3 patients had tumor re growth within the radiotherapy field, all after the end of radiotherapy. Local control improved as measured by increased frequency of tumor shrinkage and decreased frequency of primary tumor growth, recognizing the limitations of a pilot study and comparisons to best historical results achieved with standard short 5-fluorouracil schedules and radiotherapy. Successful local control largely eliminates the most common cause of refractory pain and may decrease the need for some forms of early palliative surgical intervention. Tumor shrinkage sometimes downstages tumors, creating frequent investigational opportunities for either elective extirpative surgery or intraoperative radiotherapy. This pilot experience also supports testing of expanded eligibility staging criteria for combined modality treatment and testing of new drugs as part of 5-fluorouracil-radiotherapy-based regimens.

AB - Twenty patients with inoperable locally advanced Stage II and III pancreatic cancer were treated with combined modality therapy. Radiotherapy consisted of split courses of 2000 cGy each and, as needed, an additional 1400 cGy, separated by 2-week intervals. Simultaneous multidrug regimen chemotherapy consisted of 5-fluorouracil, continuous infusion, 1 g/m2 days 1-5; streptozotocin, 300-500 mg/ m2 days 1, 2, 3; and cisplatin, 100 mg/m2 day 3 of every 4-week radiotherapy course (RT-FSP). Primary tumors decreased more than 50% in volume in II of 20 patients. Computed tomography scans demonstrated apparent complete disappearance of the primary tumor in 7 patients. Only 3 patients had tumor re growth within the radiotherapy field, all after the end of radiotherapy. Local control improved as measured by increased frequency of tumor shrinkage and decreased frequency of primary tumor growth, recognizing the limitations of a pilot study and comparisons to best historical results achieved with standard short 5-fluorouracil schedules and radiotherapy. Successful local control largely eliminates the most common cause of refractory pain and may decrease the need for some forms of early palliative surgical intervention. Tumor shrinkage sometimes downstages tumors, creating frequent investigational opportunities for either elective extirpative surgery or intraoperative radiotherapy. This pilot experience also supports testing of expanded eligibility staging criteria for combined modality treatment and testing of new drugs as part of 5-fluorouracil-radiotherapy-based regimens.

UR - http://www.scopus.com/inward/record.url?scp=0027163940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027163940&partnerID=8YFLogxK

U2 - 10.3109/07357909309024847

DO - 10.3109/07357909309024847

M3 - Article

C2 - 8485645

AN - SCOPUS:0027163940

VL - 11

SP - 241

EP - 246

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 3

ER -